Holen Sie sich die Stockscreener-App
26.95
0.86%
0.23
Handel nachbörslich:
26.91
-0.04
-0.15%
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - The Manila Times
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Can Nektar Therapeutics expand into new marketsWeekly Trade Report & AI Enhanced Trading Signals - thegnnews.com
Institutions Profited After Nektar Therapeutics' (NASDAQ:NKTR) Market Cap Rose US$80m Last Week but Retail Investors Profited the Most - 富途牛牛
Top 5 Articles of the Week: August 10-15 - Dermatology Times
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN
Nektar Therapeutics Sees Relief Buying After Extended DropEarnings Overview Summary & Fast Exit Strategy with Risk Control - sundaytimes.kr
Nektar gets FDA fast track status for alopecia areata drug - MSN
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Nektar Therapeutics shares fall 1.61% premarket as cancer research funding faces uncertainty. - AInvest
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - MarketScreener
Nektar Therapeutics’ Earnings Call Highlights Growth Potential - TipRanks
Quant Tools Rank Nektar Therapeutics as High Risk High Reward2025 Stock Rankings & AI Powered Market Entry Strategies - metal.it
Institutional investors are Nektar Therapeutics' (NASDAQ:NKTR) biggest bettors and were rewarded after last week's US$59m market cap gain - simplywall.st
Nektar Therapeutics Rebounds From Oversold Zone — Now WhatLong Term Wealth Forecast - beatles.ru
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript - Insider Monkey
How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune Disorders - Dermatology Times
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest
Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest
Nektar Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest
Nektar Therapeutics (NKTR) Stock Moves on Earnings and Fast Trac - GuruFocus
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times
Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
William Blair Maintains Nektar Therapeutics(NKTR.US) With Hold Rating - 富途牛牛
Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail
2.44%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):